Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer

GSK Investigational Site, Port Macquarie

GSK Investigational Site, Heidelberg

GSK Investigational Site, Bedford Park

GSK Investigational Site, Barcelona

GSK Investigational Site, The Bronx

GSK Investigational Site, White Plains

GSK Investigational Site, A Coruña

GSK Investigational Site, Lleida

GSK Investigational Site, Bordeaux

GSK Investigational Site, Plantation

GSK Investigational Site, Birmingham

GSK Investigational Site, Saint-Herblain

GSK Investigational Site, Rochester

GSK Investigational Site, Chicago

GSK Investigational Site, St Louis

GSK Investigational Site, Kansas City

GSK Investigational Site, New Orleans

GSK Investigational Site, Houston

GSK Investigational Site, Gilbert

GSK Investigational Site, Scottsdale

GSK Investigational Site, San Diego

GSK Investigational Site, Seattle

GSK Investigational Site, Providence

GSK Investigational Site, Ottawa

GSK Investigational Site, Toronto

GSK Investigational Site, Montreal

GSK Investigational Site, Montreal

GSK Investigational Site, Québec

GSK Investigational Site, Gyeonggi-do

GSK Investigational Site, Seoul

GSK Investigational Site, Seoul

GSK Investigational Site, Seoul

GSK Investigational Site, Manchester

GSK Investigational Site, Northwood

GSK Investigational Site, Nottingham

GSK Investigational Site, Glasgow

GSK Investigational Site, London

GSK Investigational Site, London